CN1311767A - 治疗代谢性疾病的糖皮质激素和甲状腺激素受体的配体 - Google Patents

治疗代谢性疾病的糖皮质激素和甲状腺激素受体的配体 Download PDF

Info

Publication number
CN1311767A
CN1311767A CN99809310A CN99809310A CN1311767A CN 1311767 A CN1311767 A CN 1311767A CN 99809310 A CN99809310 A CN 99809310A CN 99809310 A CN99809310 A CN 99809310A CN 1311767 A CN1311767 A CN 1311767A
Authority
CN
China
Prior art keywords
phenyl
isopropyl
sec
propyl
dibromo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN99809310A
Other languages
English (en)
Chinese (zh)
Inventor
西雷萨·阿珀尔维斯特
帕特里克·古埃迪
埃里克·霍尔姆格里
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Karo Healthcare AB
Original Assignee
Karo Bio AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Karo Bio AB filed Critical Karo Bio AB
Publication of CN1311767A publication Critical patent/CN1311767A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/78—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C217/80—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings
    • C07C217/82—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings of the same non-condensed six-membered aromatic ring
    • C07C217/90—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings of the same non-condensed six-membered aromatic ring the oxygen atom of at least one of the etherified hydroxy groups being further bound to a carbon atom of a six-membered aromatic ring, e.g. amino-diphenylethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/56—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having carbon atoms of carboxamide groups bound to carbon atoms of carboxyl groups, e.g. oxamides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C235/34—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
    • C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/90—Unsaturated compounds containing keto groups containing singly bound oxygen-containing groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/32—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing keto groups
    • C07C65/40—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing keto groups containing singly bound oxygen-containing groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/734—Ethers
    • C07C69/736—Ethers the hydroxy group of the ester being etherified with a hydroxy compound having the hydroxy group bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • C07C69/84—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring
    • C07C69/92—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring with etherified hydroxyl groups

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Dermatology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN99809310A 1998-08-05 1999-08-04 治疗代谢性疾病的糖皮质激素和甲状腺激素受体的配体 Pending CN1311767A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9816935.2A GB9816935D0 (en) 1998-08-05 1998-08-05 Novel glucocortoid and thyroid receptor ligands for the treatment of metabolic disorders
GB9816935.2 1998-08-05

Publications (1)

Publication Number Publication Date
CN1311767A true CN1311767A (zh) 2001-09-05

Family

ID=10836671

Family Applications (1)

Application Number Title Priority Date Filing Date
CN99809310A Pending CN1311767A (zh) 1998-08-05 1999-08-04 治疗代谢性疾病的糖皮质激素和甲状腺激素受体的配体

Country Status (26)

Country Link
US (1) US6492424B1 (enExample)
EP (1) EP1102739B1 (enExample)
JP (1) JP2002522407A (enExample)
KR (1) KR20010072113A (enExample)
CN (1) CN1311767A (enExample)
AT (1) ATE238267T1 (enExample)
AU (1) AU753376B2 (enExample)
BG (1) BG105214A (enExample)
BR (1) BR9912742A (enExample)
CA (1) CA2339194A1 (enExample)
DE (1) DE69907210T2 (enExample)
DK (1) DK1102739T3 (enExample)
ES (1) ES2193730T3 (enExample)
GB (1) GB9816935D0 (enExample)
HU (1) HUP0103222A3 (enExample)
ID (1) ID28805A (enExample)
IL (1) IL141106A0 (enExample)
MX (1) MXPA01001047A (enExample)
NO (1) NO20010610L (enExample)
PL (1) PL345824A1 (enExample)
SE (1) SE1102739T5 (enExample)
SI (1) SI20579A (enExample)
SK (1) SK942001A3 (enExample)
TR (1) TR200100274T2 (enExample)
WO (1) WO2000007972A1 (enExample)
ZA (1) ZA200100832B (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ513449A (en) * 1999-03-01 2004-02-27 Pfizer Prod Inc Oxamic acids and derivatives as thyroid receptor ligands
US6599942B1 (en) 1999-03-29 2003-07-29 Novartis Ag Thyromimetic organic compounds
US6790978B2 (en) 1999-03-29 2004-09-14 Novartis Ag Thyromimetic organic compounds
GB9928805D0 (en) * 1999-12-07 2000-02-02 Karobio Ab Compounds active at the Glucocorticoid and Thyroid Hormone Receptors
US6664291B2 (en) 2000-03-31 2003-12-16 Pfizer, Inc. Malonamic acids and derivatives thereof as thyroid receptor ligands
DE10038007A1 (de) * 2000-08-04 2002-02-14 Bayer Ag Neue Amino-und Amido-Diphenylether für Arzneimittel
ES2246292T3 (es) 2000-10-30 2006-02-16 Pfizer Products Inc. Moduladores de receptor glucocorticoide.
AU2001216038A1 (en) * 2000-11-14 2002-05-27 Alcon Laboratories Inc. Treatment of glaucoma and ocular hypertension
GB0029102D0 (en) * 2000-11-29 2001-01-10 Karobio Ab Compounds active at the glucocorticoid receptor
GB0029100D0 (en) * 2000-11-29 2001-01-10 Karobio Ab Compounds active at the glucocorticoid receptor
US6583180B2 (en) 2001-02-14 2003-06-24 Abbott Laboratories Glucocorticoid receptor modulators
US6777442B2 (en) * 2001-03-12 2004-08-17 Bayer Aktiengesellschaft Diphenyl derivatives
GB0111861D0 (en) 2001-05-15 2001-07-04 Karobio Ab Novel compounds
AU2002331145B2 (en) * 2001-08-24 2008-07-10 Karo Bio Ab Prime ring substituted thyroid receptor antagonists for the treatment of cardiac and metabolic disorders
GB0120691D0 (en) * 2001-08-24 2001-10-17 Karobio Ab Novel Compounds
ES2253495T3 (es) 2001-09-26 2006-06-01 Pfizer Products Inc. Acidos indol carboxilicos como ligandos de receptores tiroideos.
AU2002334675A1 (en) 2001-09-26 2003-04-07 Theravance, Inc. Substituted phenol compounds useful for anesthesia and sedation
CA2473886C (en) 2002-01-22 2012-08-21 The Regents Of The University Of California Non-steroidal ligands for the glucocorticoid receptor, compositions and uses thereof
CA2473162A1 (en) * 2002-01-30 2003-08-07 Kissei Pharmaceutical Co., Ltd. Novel thyroid hormone receptor ligand, medicinal compositions containing the same and use thereof
GB0215978D0 (en) * 2002-07-10 2002-08-21 Karobio Ab Novel compounds
AU2002951977A0 (en) 2002-10-10 2002-10-24 Leo Engineering Pty Ltd Improvements to two-part vessels
WO2005051298A2 (en) 2003-11-19 2005-06-09 Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics
WO2006128058A2 (en) * 2005-05-26 2006-11-30 Metabasis Therapeutics, Inc. Thyromimetics for the treatment of fatty liver diseases
GB0406378D0 (en) * 2004-03-22 2004-04-21 Karobio Ab Novel pharmaceutical compositions
WO2006128056A2 (en) * 2005-05-26 2006-11-30 Metabasis Therapeutics, Inc. Novel phosphinic acid-containing thyromimetics
EP2273881A1 (en) * 2008-04-15 2011-01-19 Osteogenex, Inc. Compounds and methods for altering bone growth
AU2017363206A1 (en) 2016-11-21 2019-06-13 Viking Therapeutics, Inc. Method of treating glycogen storage disease
EP3634426A4 (en) 2017-06-05 2021-04-07 Viking Therapeutics, Inc. COMPOSITIONS FOR TREATMENT OF FIBROSE
MX2020009843A (es) 2018-03-22 2020-12-11 Viking Therapeutics Inc Formas cristalinas y metodos de produccion de formas cristalinas de un compuesto.
WO2020117962A1 (en) 2018-12-05 2020-06-11 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis and inflammation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0580550T3 (da) * 1992-07-21 1998-02-02 Ciba Geigy Ag Oxamidsyrederivater som hypercholesterolæmiske midler
JP2002527355A (ja) * 1998-06-08 2002-08-27 カロ バイオ アクチェブラーグ 糖尿病の治療

Also Published As

Publication number Publication date
SE1102739T3 (enExample) 2003-08-12
US6492424B1 (en) 2002-12-10
ID28805A (id) 2001-07-05
AU5188199A (en) 2000-02-28
BG105214A (en) 2001-12-29
ZA200100832B (en) 2001-10-31
DE69907210D1 (de) 2003-05-28
WO2000007972A1 (en) 2000-02-17
AU753376B2 (en) 2002-10-17
DK1102739T3 (da) 2003-08-18
HUP0103222A2 (hu) 2002-01-28
CA2339194A1 (en) 2000-02-17
DE69907210T2 (de) 2004-02-19
EP1102739B1 (en) 2003-04-23
ATE238267T1 (de) 2003-05-15
EP1102739A1 (en) 2001-05-30
MXPA01001047A (es) 2002-09-02
KR20010072113A (ko) 2001-07-31
SE1102739T5 (enExample) 2003-09-16
JP2002522407A (ja) 2002-07-23
NO20010610L (no) 2001-04-04
GB9816935D0 (en) 1998-09-30
HUP0103222A3 (en) 2002-12-28
PL345824A1 (en) 2002-01-14
IL141106A0 (en) 2002-02-10
ES2193730T3 (es) 2003-11-01
NO20010610D0 (no) 2001-02-05
BR9912742A (pt) 2001-05-02
SI20579A (sl) 2001-12-31
SK942001A3 (en) 2001-12-03
TR200100274T2 (tr) 2001-09-21

Similar Documents

Publication Publication Date Title
CN1311767A (zh) 治疗代谢性疾病的糖皮质激素和甲状腺激素受体的配体
CN1290848C (zh) 作为治疗或预防糖尿病的二肽基肽酶抑制剂的β－氨基四氢咪唑并(1,2－A)吡嗪和四氢三唑并(4,3－A)吡嗪
CN100344616C (zh) 用于治疗代谢失调的化合物
CN1280575A (zh) 新型三环化合物和其作为药物的用途;其制备方法和包含该化合物的药物组合物
CN1287487A (zh) 氨基苯氧基乙酸衍生物和含有它们的药用组合物
CN1092407A (zh) 新的环乙烷亚基衍生物
CN1886134A (zh) 有效的抗糖尿病化合物的盐和多晶型物
CN1351597A (zh) 抗糖尿病的新型多晶形物、其制备方法和含有它们的药物组合物
CN1780614A (zh) 用于治疗代谢紊乱的化合物
CN1750758A (zh) 用于治疗代谢紊乱的化合物
CN1212861C (zh) 以NF－κB抑制剂为有效成分的心肌炎、扩张型心肌病和心衰的预防或治疗药
CN1281443A (zh) 双环化合物、其制备方法和包含它们的药物组合物
CN1774244A (zh) 用于治疗代谢紊乱的化合物
CN1302206A (zh) 喹啉衍生物的治疗用途
CN1558905A (zh) 茚满乙酸衍生物及其作为药物、中间体的用途以及制备方法
CN1708486A (zh) 二苯基乙烯化合物的新型杂环类似物
CN1777576A (zh) 用于治疗代谢紊乱的化合物
CN1697828A (zh) 新颖的化合物和它们在医药中的用途、它们的制备方法与含有它们的药物组合物
CN1642904A (zh) 那格列奈的盐
CN1675154A (zh) 抑制巨噬细胞移动抑制因子(mif)的细胞因子或生物活性的萘衍生物
JP3491635B2 (ja) ジヒドロナフタレン誘導体化合物およびその化合物を有効成分とする薬剤
CN1993120A (zh) 用于治疗阿尔茨海默氏病的芳基乙酸和相关化合物
CN1835743A (zh) 用于治疗代谢紊乱的化合物
CN101044127A (zh) 用作纤溶酶原激活剂抑制剂－1的噻唑基－萘基酸
CN1728992A (zh) 具有降低血清葡萄糖和降低血清脂质活性的α－苯硫基羧酸和α－苯氧基羧酸的用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1074567

Country of ref document: HK